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Abstract The inhibition of a-glucosidase and glucose-6-phosphatase, two enzymes involved in the carbohydrate meta-
bolism, is an important target to control glycaemia on individuals with type 2 diabetes. In this work we report for the first
time the inhibition of both enzymes by the antihyperglycemic n-butanol extract from Genista tenera (Fabaceae). This
extract decreased a-glucosidase and glucose-6-phosphatase activities to 0.97 and 80.25 %, respectively, being more
effective than acarbose, and phlorizin, the positive controls, which reduced enzymes activities only to 17.39 and 96.06 %.
Once inflammation and oxidative stress are related to diabetic impairments, the anti-inflammatory activity of the extract
was also evaluated, through its inhibitory activity over COX-1 enzyme (47.5 % inhibition). Moreover, after induction of
oxidative stress by UV radiation, the viability of irradiated rat liver hepatoma cells exposed to the extract was significantly
higher (67.82 %) than that promoted by ascorbic acid, the positive control (45.05 %). In addition, the stability of the
extract under gastrointestinal conditions was evaluated by HPLC–DAD-ESI–MS/MS. Flavonoid diglycosides were
identified as the main constituents of the extract, and no alterations in the chemical composition nor in the antioxidant
activity were observed after in vitro digestion with artificial gastric and pancreatic juices.
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1 Introduction
Type 2 diabetes is a major public health concern, due to the
increasing incidence in developed and developing coun-
tries. The loss of patient’s quality of life, the economic
burden associated with direct and indirect costs, the rele-
vant morbidity, and increased mortality reinforce the needs
to investigate new treatments and preventive options aim-
ing to control diabetes. There is evidence that hypergly-
caemia results in the generation of reactive oxygen species
and a link between oxidative stress, inflammatory response
and diabetes is now well established [1]. Antioxidants are
known to exert beneficial effects in ameliorating the inju-
rious effects of hyperglycaemia in different in vitro and
in vivo models [2] and the intake of natural antioxidants,
like polyphenols, is able to modulate a number of chronic
inflammatory diseases including type 2 diabetes [3].
Amongst the phenolic compounds, flavonoids have been
associated with beneficial effects reducing the risk of
cancer, diabetes, cardiovascular and brain diseases. These
effects are related to their radical scavenging effect along
with other possible mechanisms such as anti-inflammatory
properties [4]. Epidemiological, in vitro and in vivo studies
support the beneficial effect of dietary flavonoids on glu-
cose and lipid homeostasis and a review of the recent
findings on the antidiabetic effects of dietary flavonoids, in
particularly their cellular and molecular mechanisms of
action, has been reported [5]. So, the screening of chemical
candidates from herbal medicines is a promising approach
for new drugs discovery to the prevention and treatment of
diabetes and related complications [6]. Extracts and/or
natural molecular entities can act on several mechanisms of
type 2 diabetes and enzymes that regulate glucose meta-
bolism are potential targets for controlling glucose balance
and thereby blood glucose levels in diabetic patients [7]. A
therapeutic approach to prevent hyperglycaemia is to retard
the absorption of glucose through the inhibition of alpha-
glucosidase. Inhibitors can prolong the overall carbohy-
drate digestion time and cause a reduction in the rate of
glucose absorption, blunting the postprandial plasma glu-
cose rise [8]. Glucose-6-phosphatase catalyses the final
step of both hepatic gluconeogenesis and glycogenolysis
and its inhibition also contributes to the reduction of
endogenous glucose production [7].
Genista tenera (Fabaceae) is a medicinal plant used in
the island of Madeira, Portugal, to control diabetes. Pre-
vious studies have shown that its n-butanol extract exhibits
a significant antihyperglycemic activity on an animal
model with diabetes induced by STZ, and no acute cyto-
toxicity or genotoxicity to human lymphocytes was
observed in an in vitro assay [9]. Aiming to investigate the
mechanism of action of this antidiabetic extract we report
now the first studies concerning its inhibition of a-
glucosidase and glucose-6-phosphatase enzymes. Since
oxidative stress and inflammation are also related to dia-
betes impairments, the effect of the extract on cell viability
after UV radiation injury and the inhibition of COX-1
enzyme were also evaluated. Finally, extract stability after
in vitro digestion is also here reported for the first time.
2 Results and Discussion
2.1 Effect on Alpha-Glucosidase and Glucose
6-Phosphatase Inhibition
The inhibitory activity of G. tenera n-butanol extracts on
a-glucosidase and glucose-6-phosphatase was evaluated by
spectrophotometry-based assays. The inhibition of a-glu-
cosidase activity is of crucial importance in delaying
absorption of dietary carbohydrates that contribute to
postprandial hyperglycaemia in individuals with type 2
diabetes and is one important mechanism for the manage-
ment of the diabetic condition [8, 10, 11]. The percentage
activity of this enzyme, in the presence of G. tenera n-
butanol extract, compared to the positive and negative
controls, is depicted in Fig. 1I. The extract decreased
enzyme activity to 0.97 % when compared to the com-
mercial inhibitor acarbose, the positive control, which
reduced enzyme activity only up to 17.39 %. These results
suggest that inhibition of a-glucosidase plays an important
role in the mechanism of the antihyperglycemic action of
G. tenera n-butanol extract, thus contributing more effec-
tively to the control of postprandial glycaemia in type 2
diabetes. Glucose-6-phosphatase is the enzyme that catal-
yses the final step of gluconeogenesis and glycogenolysis
and its inhibition is also extremely important to control
hyperglycaemia in diabetic patients [7, 12, 13]. The extract
showed a tendency to inhibit this enzyme, whose activity
decreased to 80.25 %, and revealed to be more effective
than the positive control phlorizin, for which a remaining
enzyme activity of 96.06 % was found, as shown in
Fig. 1II.
Flavonoids are reported to inhibit alpha-glucosidase [8]
and to alter hepatic gluconeogenic enzymes activity
thereby reducing the endogenous glucose production [7],
which suggests that the inhibitory activity of the G. tenera
n-butanol extract can be attributed to its flavonoid
composition.
2.2 Anti-inflammatory Activity
It is well established that inflammation is also involved in
diabetic impairments. In this context, a preliminary eval-
uation of the anti-inflammatory activity of G. tenera
butanol extract was assessed by an in vitro assay, involving
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the inhibition of cyclooxygenase (COX, or Prostaglandin-
H synthase, PGHS), a key enzyme in the synthesis of
prostaglandin H2, which is a precursor for the biosynthesis
of prostaglandins (PGs), thromboxanes, and prostacyclins.
PGs support the release of further mediators of inflamma-
tion and cause the typical symptoms at inflammation sites.
Therefore, PGHS has been regarded for a long time as an
important target of most non-steroidal anti-inflammatory
drugs (NSAIDs). We found that the n-butanol extract
inhibited COX-1 enzyme (47.5 % inhibition at 0.5 mg/
mL), and presented an IC50 = 291.60 lg/mL, which was
compared with indomethacin (IC50 = 60 lg/mL), a widely
used NSAIDs.
2.3 Effect on Cell Viability
The influence of the extract on cell viability was also
studied using the MTT method. The ability of cells to
reduce MTT gives an indication of its integrity and meta-
bolic activity, which in turn may be interpreted as a mea-
sure of cell viability. We studied the effect of G. tenera n-
butanol extract on rat liver hepatoma cells (H-4-II-E), non-
irradiated, and irradiated with UV-C radiation. The extract
seems to have a positive effect on non-irradiated cells
growth, once no statistically significant differences were
observed when compared to ascorbic acid, the positive
control. The viability of irradiated cells exposed to G.
tenera n-butanol extract was significantly higher
(67.82 ± 22.36 %) than that of non-treated cells
(38.18 ± 7.73 %) and that promoted by the ascorbic acid
(45.05 ± 26.35 %). So, the present study adds further
support to the antioxidant properties of G. tenera extracts
[9] and unveils new potential applications of the plant in
long term protection against UV-related cellular damaging.
2.4 Chemical and Biological Stability After In Vitro
Digestion
In view of a potential use of G. tenera extract as a source of
nutraceuticals, its stability under gastrointestinal conditions
was analysed by HPLC. The extract was submitted to an
Fig. 1 I Activity of rat small intestine a-glucosidase in the presence
of G. tenera n-butanol extract. The activity was determined using
maltose as substrate and acarbose as positive control. Each value is
expressed as mean ? standard deviation from a total of five
replicates; II Activity of glucose-6-phosphatase from rabbit liver
microsomes in the presence of G. tenera n-butanol, extract. The
activity was determined using glucose-6-phosphate as substrate and
phlorizin as positive control. Each value is expressed as mean ? s-
tandard deviation from a total of 12 tests. For both assays the enzyme
activity in the presence of the inhibitor is expressed in percentage of
the enzyme activity without inhibitor (100 %). The same concentra-
tions of extract, acarbose and phlorizin were used, 400 mg/L. Indexes
(a–c) indicate statistically significant differences P\ 0.05 analysed
by the Tukey a posteriori test
Fig. 2 In vitro gastric and pancreatic digestions of G.tenera n-
butanol extract analysed by HPLC–DAD:7-O-glucosyl-8-glucosyl-
genistein (1), 8-(glucosyloxyglucosyl)genistein (2), 4´,7-di-O-gluco-
sylgenistein (3), 6,8-diglucosylapigenin (4), unknown (5*),
8-[apiosyl-(1 ? 6)-glucosyl]genistein (6), 30,7-di-O-glucosylluteolin
(7), rutin (8), and 3-O-rutinosylisorhamnetin (9)
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in vitro digestion with artificial gastric and pancreatic jui-
ces and none of its constituents suffered hydrolysis
(Fig. 2). Furthermore, the antioxidant activity was moni-
tored throughout the digestion by the DPPH method. The
IC50 value for DPPH extinction was 214.2 ± 0.3 lg/mL
and, after 4 h digestion with gastric and pancreatic juices,
this activity was 101.4 ± 10.7 and 112.1 ± 13.9 % of the
initial, respectively. Hence, this extract may pass through
the gastrointestinal tract keeping its composition, antioxi-
dant capacity and therefore its biological properties.
2.5 Chemical Analysis
Aiming to identify the phytochemical composition of the
extract, HPLC–DAD and HPLC–ESI–MS/MS analyses
were performed. Nine peaks were detected (Fig. 2), before
and after in vitro digestion, and chromatograms showed the
same flavonoid profile, which structures are depicted in
Fig. 3. The tentative identification of each peak (Table 1)
was based on the fragmentation patterns in MS2 and MS3
experiments, UV spectra, and comparison with literature
and MassBank database [14]. The MS2 spectrum of the
deprotonated molecule of compound 1 at m/z 593 presents
losses of 120 Da (0,2X-) and 90 Da (0,3X-) characteristic
of a C-glucosyl flavonoid [15], affording the fragment ions
at m/z 473 and 503, respectively. Waridel et al. [16]
reported that the low abundance of the 0,3X- fragment can
be correlated with the glycosylation position, namely with
glycosylation at C-8, suggesting that the relatively low
abundance of 0,3X- found for compound 1 indicates gly-
cosylation at the C-8 position. From the DAD data, it can
be inferred that the aglycone is an isoflavone, with the
characteristic maximum wavelength at 261 nm and a
shoulder at 295 nm, while flavones present also an intense
band at 330–365 nm. Furthermore, the MS3 spectrum of
the ion at m/z 473 shows a loss of 162 Da, a glucosyl
moiety, which is indicative of an O-glucoside, suggesting
that compound 1 is 7-O-glucosyl-8-glucosylgenistein. The
deprotonated molecule of compound 2, m/z 593 loses
252 Da resulting from the combined loss of glucosyl
moiety and one 0,3X fragment and 282 Da, attributed to a
combined loss of glucosyl moiety and 0,2X fragment,
affording the ions at m/z 341 and 311, respectively, the
latter with 100 % intensity. This behaviour suggests that a
glucosylglucoside moiety is C–C linked to genistein, in
accordance also with the observed UV absorption maxima.
Table 1 Putative identification of glycosyl flavonoids from Genista tenera n-butanol extract, by HPLC–DAD and HPLC-ESI–MSn
Peak Rt (min) kmax (nm) [M-H]
- m/z Product ions ESI–MSn (relative abundance, %) Identification (Massbank score
and record)
1 7.1 261, 295 sh 593 [MS2 593]: 503 (2), 473 (100)
[MS3 473]: 473 (100), 445 (24), 383 (2),
353 (2), 311 (12) 310 (25), 282 (12)
7-O-Glucosyl-8-glucosylgenistein
2 8.2 258, 290 sh 593 [MS2 593]: 503 (\1), 341 (5), 311 (100), 283 (7)
[MS3 311]: 311 (15), 283 (100), 267 (1)
8-(Glucosyloxyglucosyl)genistein
3 8.7 261, 271 sh,
322 sh
639a [MS2 639]: 593 (10), 591 (2), 431 (100), 269 (2)
[MS3 431]: 431 (25), 355 (4), 323 (5), 311 (8),
283 (9), 268 (100)
4´,7-Di-O-glucosylgenistein
4 9.2 272, 293,
301, 314
593 [MS3 593]: 575 (8), 503 (30), 473 (100),
455 (4), 383 (22), 353 (39)
[MS3 473]: 455 (2), 383 (17), 353 (100)
6,8-Diglucosylapigenin
5 9.6 – 563 – Unknown
6 10.5 261, 290 sh 563 [MS2 563]: 341 (6), 311 (100), 283 (11)
[MS3 311]: 311 (100), 283 (39)
8-[Apiosyl-(1 ? 6)-glucosyl]-
genistein
7 12.2 240, 263,
322
609 [MS2 609]: 447 (100), 285 (6)
[MS3 447]: 447 (2), 285 (100)
30,7-Di-O-glucosylluteolin
(0.6758, PR100804)
8 13.6 241, 257,
294, 350
609 [MS2 609]: 447(2), 343 (8), 301 (100), 271 (8),
255 (4), 179 (3)
[MS3 301]: 301 (100), 271 (42), 255 (28),
239 (3), 229 (3), 211 (1), 179 (44)
Rutin (0.4606, PR100804)
9 15.1 239, 257,
293, 348
623 [MS2 623]: 315 (100), 300 (19), 271 (5), 255 (3)





a This compound ionized as [M ? HCOO]-
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The loss of 28 Da (CO) observed in MS3 may result from
contraction of ring C, which is commonly detected in
isoflavones [17, 18]. Two consecutive losses of 162 Da
indicate that compound 3 is a flavonoid diglucoside,
showing an Y1
- ion at m/z 431. However, this compound
ionizes as [M ? HCOO]- turning its assignment more
difficult. Nevertheless, the fragmentation pattern is con-
sistent with 4´,7-di-O-glucosylgenistein. The formation of
[M ? HCOO]- although uncommon, has been reported in
the literature for several compounds [19–21]. The DAD
data suggest that compound 4 could be either a flavone or a
flavonol since it exhibits an intense band II (314 nm). In
mass spectrometry, C-glycosyl flavones suffer cross-ring
cleavages of sugar residues yielding ions produced by
losses of 90 and 120 Da, thus allowing differentiation from
O-glycosyl flavones with losses of 162 Da for hexose,
146 Da for rhamnose and 132 Da for pentose moieties
respectively [22]. The MS2 spectrum of the deprotonated
molecule of compound 4, m/z 593, presents the character-
istic losses of a C-glucosyl flavonoid, i.e. the loss of 90 Da
affording a 0,3X- ion (m/z 503) and 120 Da affording a
0,2X- ion (m/z 473). The MS3 of the ion at m/z 473 presents
similar losses (90 and 120 Da), which can be indicative of
a di-C-glucosyl flavonoid. A literature survey enabled us to
propose compound 4 to be 6,8-diglucosylapigenin, since
there is a close agreement between the data available in the
literature [22, 23] with data acquired by us. The DAD data
for compound 6 suggests that it is an isoflavone. The loss of
252 Da suggests the presence of a C–C linked apiosyl-
glucosyl moiety, affording the ion 0,2X- ion at m/z 311
bearing the apiosyl group. The characteristic loss of
222 Da is also detected by the presence of the 0,3X- ion
also bearing the apiosyl group at m/z 341. The MS3 of the
ion at m/z 311 shows the loss of 28 Da, characteristic of an
isoflavone. Interestingly, it was found that retro-Diels–
Alder fragments, that are observed in flavones, flavanones,
flavonols and chalcones were not found in the isoflavones
studied, corroborating the results reported by Wang et al.
[24] and references cited therein. Hence, the analysis of the
data obtained for compound 6 suggests the structure of
8-[apiosyl-(1 ? 6)-glucosyl] genistein previously assigned
by Peng et al. [25]. The fragments obtained for compounds
7 (30, 7-di-O-glucosylluteolin), 8 (rutin), and 9 (3-O-ruti-
nosylisorhamnetin) were identified based on MassBank
scores and records (Table 1).
In conclusion, Genista tenera n-butanol extract showed
a significant inhibition of glucose-6-phosphatase and alpha-
glucosidase enzymes, which denotes a physiologically
important role in the metabolism of carbohydrates, and
suggests a possible mechanism of action for its antihy-
perglycemic activity. Moreover, the anti-inflammatory
capacity of the extract, and its protective effect against UV-
radiation injury are reliable properties that can be attributed
to flavonoid diglycosides, the main components of the
extract. These components are able to pass the gastroin-
testinal tract, maintaining their chemical structure and
antioxidant activity. The present work adds further support
to the previously reported bioactivities of flavonoids from
G. tenera extracts and contributes to the valorisation of this
plant as a source of bioactive compounds that can be
regarded as potential prototypes for the generation of new
antidiabetic agents with anti-inflammatory and antioxidant
properties.
3 Experimental
3.1 Chemicals and Reagents
The following reagents used for the evaluation of a-glu-
cosidase and glucose-6-phosphatase inhibition were
Fig. 3 Structures of the flavonoids identified in the n-butanol extract
of G. tenera
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purchased from Sigma (St. Louis, MO, USA): rat intestine
acetonic fraction, 0.1 M maleate buffer (pH 6.9), maltose,
diagnostic kit for the determination of glucose (GO),
acarbose, glucose-6-phosphate, glucose-6-phosphatase,
HEPES (pH 6.5), EDTA, DMSO, and phlorizin.
To evaluate cell viability, the reagents MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide],
dimethyl sulfoxide (DMSO), minimum essential medium
(MEM), foetal calf serum (FCS), trypsin, phosphate buf-
fered saline(PBS), amphotericin B, penicillin and strepto-
mycin were purchased from Sigma (St. Louis, MO, USA).
The H-4-II-E (rat hepatoma) cells were purchased from the
European Collection of Cell Cultures.
Cyclooxygenase 1 from sheep (Sigma-Aldrich, Barce-
lona, Spain) was used to evaluate the anti-inflammatory
activity. For the HPLC analysis of the extracts, HPLC-
grade methanol and trifluoroacetic acid were purchased
from Merck (Darmstadt, Germany). For the antioxidant
activity and in vitro digestions with gastric and pancreatic
artificial juices, 2,2-diphenyl-1-picrylhydrazyl (DPPH),
pepsin and pancreatin were obtained from Sigma-Aldrich
(Barcelona, Spain), while potassium phosphate buffer salts
were purchased from Merck (Darmstadt, Germany). All
reagents used in the present work were of analytical grade.
3.2 Plant Identification and Extract Preparation
The plant was collected in Porto Novo, Island of Madeira,
and identified by Dr. Roberto Jardim. A voucher specimen
(MADJ 10673) is deposited in the Herbarium of Jardim
Botaˆnico da Madeira, Funchal, Portugal.
The powdered plant aerial parts (487.30 g) were
exhaustively extracted with ethanol (3 9 2.5 L) at room
temperature. The ethanol solution was filtered (Whatman
no. 4) and concentrated to dryness in a rotary evaporator at
40 C and low pressure, giving a crude extract (62.19 g) to
which hot (80–90 C) distilled water (500 mL) was added.
The aqueous fraction was then filtered and extracted
sequentially by partition with diethyl ether (3 9 500 mL),
ethyl acetate (3 9 500 mL) and n-butanol (3 9 500 mL).
Solvents were evaporated under vacuum to give the diethyl
ether (1.23 g), ethyl acetate (5.19 g), and n-butanol
(5.16 g) dried extracts.
3.3 Enzyme Inhibition Assays
3.3.1 a-Glucosidase Inhibition
Enzyme solutions were prepared using rat intestinal ace-
tone powder as the source of a-glucosidase. Rat intestinal
acetone powder (50 mg) was homogenized with maleate
buffer 0.1 M, pH 6.9 (10 mL) and centrifuged at
60009g for 20 min at 4 C. The supernatant obtained was
used as the enzyme solution for the a-glucosidase reaction.
Before starting the test, extract samples were dissolved in
dimethyl sulfoxide (DMSO) at a concentration of 20 mg/
mL. Then, each sample (10 lL) was diluted with maleate
buffer 0.1 M, pH 6.9 (90 lL). Experimental procedure for
a-glucosidase inhibition was conducted according to the
method of Mai et al. [11] with some modifications. Enzyme
solution (50 lL) was pre-incubated with the extract solu-
tion (50 lL) and maleate buffer 0.1 M, pH 6.9 (100 lL) at
37 C for 10 min, and then the enzyme reaction was started
by adding maltose substrate solution (50 lL, 1 % w/v in
maleate buffer 0.1 M, pH 6.9). The enzymatic reaction was
allowed to proceed at 37 C for 10 min, and then stopped
by heating at 100 C for 5 min. The reaction mixture was
kept in ice bath. The generated glucose was measured with
a commercial glucose assay kit (GO) at 540 nm, in a
Hitachi U-2000 spectrophotometer. A negative control was
run with maleate buffer 0.1 M, pH 6.9 (150 lL) in the
absence of the extract. For blank determination, the
enzyme solution was replaced by maleate buffer 0.1 M, pH
6.9 (50 lL), and the same procedure as described above
was carried out. Acarbose was used as a reference com-
pound and tested at the some concentration of the extract
(400 mg/L). A total of five separate trials were carried out.
The a-glucosidase activity is expressed in percentage of the
activity of the free enzyme.
3.3.2 Glucose-6-Phosphatase Inhibition
Enzyme solution was prepared with rabbit liver micro-
somes as a source of glucose-6-phosphatase. This solution
was prepared according to the method of Marccuci et al.
[26] cited by Estrada et al. [13]. Briefly, microsomal pro-
tein (16.74 mg) was homogenized with HEPES 5 mM, pH
6.5 (0.837 mL), sucrose (0.25 mM) and MgCl2 (1 mM)
and frozen at -80 C until use. Before starting the test,
extract samples were dissolved in dimethyl sulfoxide
(DMSO) at a concentration of 20 mg/mL. Then, each
sample (40 lL) was diluted with HEPES 16 mM, pH 6.5
(60 lL). Experimental procedure for glucose-6-phos-
phatase was conducted according to the method described
in Estrada et al. [13], with some modifications. In brief,
phlorizin (5.5 lL) and extracts (5 lL) were previously
incubated with the enzyme (2.5 lL) at 37 C for 40 min
and G-6-P solution was added to start the reaction. The
glucose-6-phosphatase assay was carried out in a final
volume of 100 lL, with glucose-6-phosphate (5 mM),
EDTA (2 mM), HEPES, pH 6.5 (16 mM) and the enzyme
mixture. The reaction was carried out at 37 C for 60 min,
without shaking, and was stopped by the addition of 1 mL
of ammonium molybdate (0.28 %), SDS (1.11 %) and
ascorbic acid (1.11 %) in sulphuric acid (0.33 M). The
reaction was incubated at 47 C for 20 min and the
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absorption at 820 nm was recorded in a Hitachi U-2000
spectrophotometer. The final concentration of DMSO in
experimental assays was 2 %. Phlorizin was dissolved in
DMSO (10 %) and used as positive control in the same
concentration as the extracts (400 mg/L). A total of twelve
separate trials was carried out. The glucose-6-phosphatase
activity is expressed in percentage of the activity of the free
enzyme.
3.3.3 COX-1 Inhibition
COX-1 (EC 1.14.99.1) activity was measured by following
spectrophotometrically at 611 nm the oxidation of TMPD
with arachidonic acid. This assay was performed as descri-
bed in [27], with some modifications. Briefly, to Tris–HCl
buffer 100 mM, pH 8 (1000 lL) COX-1 enzyme (200 units
dissolved in Tris–HCl buffer, 50 lL) was added and the co-
factor of hematin dissolved in Tris–HCl buffer (100 lL,
3 lM in the assay). After 5 min, the enzyme was reconsti-
tuted and then a solution of plant extract or a standard inhi-
bitor inDMSO (50 lL) and pureDMSO (50 lL)were added
and pre-incubated for 3 min at 25 C. After the incubation
time has expired, TMPD dissolved in Tris–HCl buffer
(200 lL, 100 lM in the assay) was added. The reaction was
initiated by the addition of arachidonic acid dissolved in
DMSO (50 lL, 100 lM in the assay) to the enzyme/extract
mixture and contents were mixed immediately. The initial
velocity of the reaction was measured following the oxida-
tion reaction of TMPD at 611 nm for 30 s. The inhibition %
was calculated as follows:
I ð%Þ ¼ 100  Viwith inhibitor=Viwith out inhibitorð Þ  100
where Vi with inhibitor is the initial velocity observed at dif-
ferent inhibitor concentrations and Vi without inhibitor is the
velocity observed for enzyme samples pre-incubated for
the same time with inhibitor free in DMSO. IC50 values
were determined by regression analysis.
3.4 Cell Viability Assay
Cell viability was studied by the MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]
method. The test described below is adapted to be used
with cell cultures in growth phase.
3.4.1 Cell Culture
The H-4-II-E cells were seeded into tissue culture flasks of
75 cm2 in MEM medium supplemented with 10 % FCS
and 1 % antibiotics containing penicillin (10000 U/mL)
and streptomycin (10 mg/mL) and also 0.1 % antifungal,
amphotericin B (250 mg/mL). The cells have multiplied
freely to 80–90 % confluence at 37 C in a humidified
atmosphere of 10 % CO2 (incubation chamber Shel Lab
CO2 Series). The medium was changed every 3 days.
When the cultures were 80–90 % confluent, H-4-II-E cells
were washed with PBS (10 mL), detached with trypsin
(1 mL), counted and suspended in MEM medium to be
seeded in 96-well plates at a density of 5 9 104 cells/mL.
Assays were performed in a laminar flow camera with
biosafety class II A/B3 (Steril Gard–Baker Company).
Before starting the test, samples were dissolved in DMSO,
at a concentration of 20 mg/mL, and at least five separate
trials were made.
3.4.2 MTT Assay
MTT assay was performed according to INVITTOXMethod
N. 17 for basal cytotoxicity (ECVAM) [28]. Exponentially
growing cells (H-4-II-E) were trypsinized and suspended in
fresh media (MEM supplemented with 10 % fetal bovine
serum and 100 U/mL penicillin, and 100 mg/mL strepto-
mycin) at a density of 5 9 104 cells/mL, and this cell sus-
pension (100 lL) was plated on to each well of a 96-well
plate. Cells were incubated at 37 C, 5 % CO2 humidified
incubator for 24 h, after which the n-butanol extract and
ascorbic acid (400 mg/L), the positive control, and DMSO,
the negative control, were added. The cellswere placed in the
incubator for 1 h and then, half of the plates were exposed to
UV-C radiation (k = 257.7 nm, Philips TUV G15T8 UVC
lamp) for 5 min. Cells were further incubated until a total of
48 h and then MTT (10 lL, 10 mg/mL) was added to each
well. After 4 h incubation at 37 C themediumwas removed
and the wells were washed with cold (5 C) PBS
(100 lL).The formazan crystals were solubilized by adding
DMSO (100 lL) to each well and placing the plates in an
orbital shaker for 20 min. Colorimetric readingwas done in a
microplate reader (Beijing Perlong New Technology DNM-
9602) at 492 and 630 nm (reference k). The viability is
expressed as an average percentage of metabolically viable
cells in each group compared to control cells. Results are
averages from five separate assays.
3.5 In Vitro Digestion
The gastrointestinal digestion of the plant extract was
simulated in vitro with artificial gastric and pancreatic
juices using the method described by Fale´ et al. [19], and
the chemical composition of the digested extract was
analysed by HPLC–DAD while the remaining antioxidant
activity was measured by the DPPH method.
3.5.1 In Vitro Metabolism by the Gastric Juice
Gastric juice (2.5 mL) was added to the extract solution
(5 mg/mL) in water (2.5 mL). The mixture was incubated
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at 37 C for 4 h. Samples (100 lL) were taken hourly,
added to ice-cold methanol (900 lL) and analysed by
HPLC. The gastric juice (100 mL) consisted of pepsin
(320 mg) and NaCl (200 mg), and the pH was set to 1.2
with concentrated HCl. Assays were done in triplicate.
3.5.2 In Vitro Metabolism by the Pancreatic Juice
Pancreatic juice (2.5 mL) was added to the extract solution
(10 mg/mL) in water (2.5 mL). The mixture was incubated
at 37 C for 4 h. Samples (100 lL)were taken hourly, added
to ice-cold methanol (900 lL) and centrifuged for 5 min at
50009g. The supernatant was analysed by HPLC. The
pancreatic juice consisted of pancreatin (250 mg) in potas-
sium-phosphate buffer 50 mM, pH 8 (10 mL). Assays were
done in triplicate. Samples (200 lL) were taken at the same
time, centrifuged 5 min at 50009g and the supernatant was
analysed for antioxidant activity, against a blank with water
instead of plant extract. Assays were done in triplicate and
the concentration of the extract in the digestions varied
according to the IC50 values for antioxidant activity.
3.6 Antioxidant Activity
Antioxidant activity was evaluated by the DPPH method.
To a solution of DPPH (2.5 mL, 0.002 % in methanol),
25 lL of plant extract (100–300 lg/mL in the cuvette)
were added. The mixture was incubated for 30 min at room
temperature. The absorbance was measured at 517 nm
against a corresponding blank. The antioxidant activity was
calculated as follows:
AA %ð Þ ¼ ADPPH  ASample=ADPPH
  100
where AA is the antioxidant activity, ADPPH is the
absorption of the DPPH solution against the blank, ASample
is the absorption of the sample against the blank. The tests
were carried out in triplicate and the extract concentration
providing 50 % of antioxidant activity (IC50) was obtained
by regression analysis.
3.7 Phytochemical Analysis
HPLC analysis was carried out in an Elite LaChrom
VWR Hitachi Liquid Chromatograph equipped with a
Column Oven L-2300 and Diode Array Detector L-2455
(VWR, USA). A column LiChroCART 250-4 LiChro-
spher 100 RP-8 (5 lm) from Merck (Darmstadt, Ger-
many) was used. The extract was analysed by injecting the
sample (25 lL, 1 mg/mL) with an auto injector, and using
a gradient composed of solution A (0.05 % trifluoroacetic
acid), and solution B (methanol) as follows: 0 min, 80 %
A, 20 % B; 20 min 20 % A, 80 % B; 25 min, 20 % A,
80 % B. The flow was 1 mL/min, and the detection was
carried out between 200 and 500 nm with a diode array
detector.
LC–MS and LC–MSn analysis were carried out on a
liquid chromatograph Surveyor Plus Modular LC system
connected to a LCQ Duo ion trap mass spectrometer
equipped with an electrospray ionisation (ESI) source,
from Thermo Scientific (Bremen, Germany). The column
used was a LiChroCART 250-4 LiChrospher 100 RP-8
(5 lm) column (Merck, Darmstadt, Germany). The extract
was analysed by injection of the sample (25 lL, 10 mg/
mL) and using a linear gradient composed of solution A
(1.0 % formic acid), and solution B (methanol) as follows:
0 min, 70 % A, 30 % B; 20 min 20 % A, 80 % B; 25 min,
20 % A, 80 % B. The mass spectrometer was operated in
both positive and negative ion modes in the range m/z
120–1000 and the parameters were adjusted in order to
optimize the signal-to-noise ratios (S/N) for the ions of
interest. Briefly, the nebulizing and auxiliary gas (nitrogen)
flow rates were 40 and 20 (arbitrary units) and the capillary
temperature was set to 250 C. Collision induced dissoci-
ation (CID) experiments were performed by isolating the
ions within the ion trap and accelerating them in order to
suffer multiple collisions with the background gas present
in the ion trap (helium) using a data dependent acquisition
mode. The ions of interest were activated by applying a
percentage of a supplementary a.c. potential in the range of
0.75–1.75 Vp–p (peak-to-peak) to the end cap electrodes of
the ion trap at the resonance frequency of the selected ion
(referred to as the normalized collision energy, NCE). The
injection times were 50 ms in a full scan and 200 ms in a
MS/MS scan. XcaliburTM software from Thermo Scientific
was used to acquire and to process the data.
The identification of some extract constituents was
performed using the MassBank database (freely available
at http://www.massbank.eu/MassBank/).
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